2. Search Result
Search Result
Results for "

luciferase activity

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

3

Peptides

6

Natural
Products

1

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12684
    CH-223191
    Maximum Cited Publications
    113 Publications Verification

    		 Aryl Hydrocarbon Receptor Cancer
    CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR). CH-223191 inhibits TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibits TCDD-induced luciferase activity with an IC50 of 0.03 μM .
    CH-223191
  • HY-13250
    Silvestrol aglycone

    		Drug Derivative Cancer
    Silvestrol aglycone is a Silvestrol analogue, inhibits protein translation initiation in cancer cells, with EC50s of 10 and 200 nM for myc-LUC and tub-LUC luciferase reporter protein translation, respectively. Anti-cancer activity .
    Silvestrol aglycone
  • HY-153229
    Firefly luciferase mRNA-LNP
    1 Publications Verification

    		 mRNA Biochemical Assay Reagents Others
    Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency .
    Firefly luciferase mRNA-LNP
  • HY-145267
    OM-153

    		PARP Wnt Cancer
    OM-153 is a potent and orally active tankyrase inhibitor with IC50s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC50 value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .
    OM-153
  • HY-175357
    YAP/TEAD-IN-2

    		YAP Cancer
    YAP/TEAD-IN-2 (Compound T-1) is a YAP/TEAD inhibitor. YAP/TEAD-IN-2 inhibits the luciferase activity driven by YAP/TEAD in 293T cells. YAP/TEAD-IN-2 exhibits strong anti-proliferative activity against human pleural mesothelioma NCI-H226 cells. YAP/TEAD-IN-2 can be used for the study of diseases associated with Hippo pathway dysregulation, particularly cancers .
    YAP/TEAD-IN-2
  • HY-162723
    FOSL1 degrader 1

    		PROTACs AP-1 Cancer
    FOSL1 degrader 1 is a FOSL1 PROTAC degrader with a DC50 of 2.3 μM. FOSL1 degrader 1 induces proteasomal degradation of FOSL1. FOSL1 degrader 1 eliminates cancer stem cells in head and neck squamous cell carcinoma. FOSL1 degrader 1 suppresses head and neck squamous cell carcinoma tumorigenesis. FOSL1 degrader 1 can be used for the research of head and neck squamous cell carcinoma .
    FOSL1 degrader 1
  • HY-122234
    VPC-18005

    		DNA/RNA Synthesis Cancer
    VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity .
    VPC-18005
  • HY-15672
    FM19G11

    		HIF/HIF Prolyl-Hydroxylase Neurological Disease Cancer
    FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions .
    FM19G11
  • HY-N11422
    Mycaminosyltylonolide

    		Antibiotic Bacterial Infection
    Mycaminosyltylonolide is a potent antibiotic. Mycaminosyltylonolide shows antibacterial activity. Mycaminosyltylonolide inhibits luciferase synthesis .
    Mycaminosyltylonolide
  • HY-151480
    HP590

    		STAT Apoptosis Cancer
    HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). HP590 shows anti-proliferative activity to gastric cancer cells and induces apoptosis .
    HP590
  • HY-134258
    MEISi-1

    		HOXA Cardiovascular Disease Others Cancer
    MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer .
    MEISi-1
  • HY-160496
    STAT3-IN-25

    		STAT Cancer
    STAT3-IN-25 (Compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 has the potential for pancreatic cancer research .
    STAT3-IN-25
  • HY-160870
    Firefly luciferase-IN-3

    		Fluorescent Dye Others
    Firefly luciferase-IN-3 (CID: 17087944) is an inhibitor of ATP-dependent luciferase (Firefly luciferase) and has nM-level inhibitory activity against NanoLuc (pIC50=7.5) .
    Firefly luciferase-IN-3
  • HY-N16500
    Hericenone C

    		NF-κB Neurological Disease
    Hericenone C is a metabolite derived from Hericium erinaceus. Hericenone C inhibits LPS (HY-D1056)-induced NRE::Luc luciferase activity, reduces phosphorylation of p65 and inhibits NF-κB signaling. Hericenone C exhibits neuroprotective effect .
    Hericenone C
  • HY-161982
    JNU-0921

    		TNF Receptor Cancer
    JNU-0921 is a potent and orally active CD137 agonist. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8 + T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity .
    JNU-0921
  • HY-160873
    Firefly luciferase-IN-5

    		Fluorescent Dye Others
    Firefly luciferase-IN-5 (CID: 16031203) is an inhibitor of ATP-dependent luciferase (Firefly luciferase). It has nM-level inhibitory activity against GRLuc, RLuc8, and RLuc respectively (pIC50=8.5,7.5,5.5) .
    Firefly luciferase-IN-5
  • HY-143494
    RSV/IAV-IN-3

    		RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
    RSV/IAV-IN-3
  • HY-158257
    Firefly luciferase-IN-4

    		Fluorescent Dye Others
    Firefly luciferase-IN-4 (CID: 3987260) is an inhibitor of ATP-dependent luciferase (Firefly luciferase). It has nM-level inhibitory activity (pIC< sub>50=6.5) .
    Firefly luciferase-IN-4
  • HY-P10256A
    Kiss2 peptide acetate

    		Kisspeptin Receptor PKA PKC Endocrinology
    Kiss2 peptide acetate is the acetate form of Kiss2 pepride (HY-P10256). Kiss2 peptide acetate is a positive regulator of reproduction. Kiss2 peptide acetate binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .
    Kiss2 peptide acetate
  • HY-19498
    WAY-204688

    SIM-688

    		 NF-κB Inflammation/Immunology
    WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.
    WAY-204688
  • HY-D1343
    DMNPE-caged D-luciferin

    		Fluorescent Dye
    DMNPE-caged D-luciferin is a heterocyclic luminescent compound that is a natural ligand for luciferase, an enzyme used to detect cell activity. Its reaction requires ATP and emits yellow-green light with a peak wavelength of about 530 nm. The luciferin in the DMNPE cage easily crosses the cell membrane.
    DMNPE-caged D-luciferin
  • HY-160686
    GSK248233A

    		VEGFR Others
    GSK248233A is a dual inhibitor of Fluc and VEGFR2 with IC50 of 1.03 μM and 2 nM, respectively. GSK248233A also shows activity against the AGC family. GSK248233A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays .
    GSK248233A
  • HY-N12011
    11-Oxoisomogroside V

    		PGC-1α Others
    11-Oxoisomogroside V (compound 3) is a cucurbitacin isolated from the crude extract of Luo Han Guo. 11-Oxoisomogroside V activates the transcriptional activity of PGC-1α. In the luciferase experiment, the results showed that 10 μM and 20 μM 11-Oxoisomogroside V could increase the luciferase activity to 133.79% and 143.81% .
    11-Oxoisomogroside V
  • HY-W106688
    Triisopropyl phosphate

    		Estrogen Receptor/ERR Endocrinology
    Triisopropyl phosphate inhibits TFF1 and EGR3 gene expression, exhibits anti-estrogenic activity that inhibits Estradiol (HY-B0141)-induced MCF-7 cell proliferation with an EC50 of 341 μM. Triisopropyl phosphate inhibits the estrogen response element (ERE)-stimulated luciferase activity in MVLN cells with an EC50 of 900 μM .
    Triisopropyl phosphate
  • HY-107595
    SD-1008
    1 Publications Verification

    		 JAK STAT Apoptosis Cancer
    SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway .
    SD-1008
  • HY-N4308
    Hexamethylquercetagetin

    Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone

    		 NF-κB IKK Bcl-2 Family Cancer
    Hexamethylquercetagetin (Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone) is an orally active NF-κB inhibitor. Hexamethylquercetagetin inhibits NF-κB-derived luciferase activity, reduces phosphorylated p65 and IκBα, Cyclin D1, Bcl-2 and blocks TNFα-induced NF-κB activation. Hexamethylquercetagetin inhibits survival and proliferation of cervical carcinoma cells. Hexamethylquercetagetin suppresses tumor volume and weight in BALB/c nude mouse xenograft models of cervical carcinoma. Hexamethylquercetagetin can be used for the research of cancer, such as cervical carcinoma .
    Hexamethylquercetagetin
  • HY-159912
    pan-TEAD-IN-1

    		YAP Cancer
    pan-TEAD-IN-1 (Compound 3) is an orally active pan-TEAD inhibitor targeting the palmitoylation site of TEAD, disrupting its interaction with the coactivators YAP/TAZ, thereby suppressing the transcriptional upregulation of oncogenes (e.g., Ctgf and Cyr61) in the Hippo signaling pathway. pan-TEAD-IN-1 exhibits excellent activity with a luciferase IC50 of 0.36 nM and an H226 cell IC50 of 1.52 nM. It also shows favorable pharmacokinetics (AUC0–∞ = 228.7 μg/mL·min, T1/2 = 183.9 min). In TEAD-dependent xenograft mouse models, pan-TEAD-IN-1 significantly inhibited tumor growth, showing promise for research in TEAD-dependent cancers .
    pan-TEAD-IN-1
  • HY-153230
    Firefly luciferase circRNA-LNP

    		Liposome Biochemical Assay Reagents Others
    Firefly luciferase circRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase circRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .
    Firefly luciferase circRNA-LNP
  • HY-163470
    Luciferase activator-1

    		Reactive Oxygen Species (ROS) Others
    Luciferase activator-1 (Compound D2) is an activator for luciferase, which increases the luciferase activity up 1.04 fold (at the concentration of 50 nM) .
    Luciferase activator-1
  • HY-P10256
    Kiss2 peptide

    		Kisspeptin Receptor PKA PKC Endocrinology
    Kiss2 peptide is a positive regulator of reproduction. Kiss2 peptide binds with its cognate receptor Kiss2R (GPR54) in COS-7 cells, activates PKA and PKC signaling pathways through Gas and Gaq proteins, and thus enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc) .
    Kiss2 peptide
  • HY-153982
    PPARγ agonist 8

    		PPAR Metabolic Disease
    PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC50 of 0.2 μM .
    PPARγ agonist 8
  • HY-147747
    HSP90-IN-12

    		HSP Cancer
    Among vibsanin a analogues, vibsanin a analog C (VAC) showed anti proliferative effect on various cancer cell lines, and the anti proliferative activity was the strongest among vibsanin a analogues. In addition, VAC fluctuated the amount of hsp90 related proteins in cells and inhibited hsp90 mediated protein refolding of luciferase in vitro.
    HSP90-IN-12
  • HY-139855
    ZG-2033

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2033 (Compound 26) is an orally active HIF-2α agonist that demonstrates nanomolar activity in luciferase reporter gene assays (EC50 = 490 nM). ZG-2033 has the effect of alleviating anemia and exhibits synergistic action with AKB-6548 (HY-101277) in anemia, and can be used in the study of renal anemia .
    ZG-2033
  • HY-106827S1
    Trimegestone-13C,d3

    RU 27987-13C,d3

    		 Androgen Receptor Phosphatase Progesterone Receptor Isotope-Labeled Compounds Endocrinology
    Trimegestone- 13C,d3 is 13C and deuterated labeled Trimegestone (HY-106827). Trimegestone (RU 27987) is an orally active 19-norpregnane progestin. Trimegestone binds to progesterone receptor (PR) with an IC50 value of 3.3 nM (rat PR). Trimegestone increases alkaline phosphatase activity (EC50=0.1 nM) but not luciferase activity. Trimegestone also shows a weak antiandrogenic activity (weak androgen receptor affinity). Trimegestone can be used in studies of contraception or menopausal syndromes .
    Trimegestone-13C,d3
  • HY-121888
    20-HEPE

    		PPAR Metabolic Disease
    20-HEPE is a metabolite of eicosapentaenoic acid formed by ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. At 10 μM, it activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter gene. 20-HEPE also activates mouse transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks analgesic activity in rats.
    20-HEPE
  • HY-134997
    4-Oxo Docosahexaenoic Acid

    4-oxo DHA

    		 PPAR Cancer
    4-oxo Docosahexaenoic acid (4-oxo DHA) is a putative metabolite of Docosahexaenoic acid (HY-B2167) with antiproliferative and PPARγ agonist activity. It inhibits the growth of several triple negative breast cancer cell lines (MCF-10F, trMCF, bsMCF, MDA-MB-231, and BT549) at 50-100 μM, however it increased proliferation of MCF-7 cells. 4-oxo DHA binds covalently to PPARγ and activates gene transcription in luciferase reporter assays and in dendritic cells with EC50 values of approximately 8-16 μM.
    4-Oxo Docosahexaenoic Acid
  • HY-182673
    VT102

    		YAP Cancer
    VT102 is a TEAD1 inhibitor with a human IC50 of 391 nM. VT102 inhibits auto-palmitoylation, attenuates YAP/TEAD1 interaction, reduces expression of TEAD target genes, and inhibits YAP-mediated luciferase reporter activity. VT102 exerts weak cell growth inhibitory activity in cancer cells. VT102 can be used for the research of cancer .
    VT102
  • HY-179559
    OPN-9643

    		YAP Cancer
    OPN-9643 is a covalent inhibitor targeting the central palmitate binding pocket of TEADs with an IC50 of 15 nM, preventing autopalmitoylation and reducing TEAD-driven luciferase activity and canonical TEAD targets, CTGF and CYR61. OPN-9643 can be used for the research of cancer, such as melanoma .
    OPN-9643
  • HY-N12481
    Cephalandole B

    		Others Inflammation/Immunology
    Cephalandole B is an indigo alkaloid that has the activity of inhibiting IL-17A gene expression. Cephalandole B significantly inhibited the activity of IL-17A luciferase reporter gene in Jukat cells, and this inhibitory effect was dose-dependent. Cephalandole B may have important application prospects in inflammation-related research .
    Cephalandole B
  • HY-17437C
    (Rac)-Mefloquine

    (Rac)-Mefloquin

    		 NF-κB IKK Apoptosis Cancer
    (Rac)-Mefloquine ((Rac)-Mefloquin) is an orally active NF-κB inhibitor. (Rac)-Mefloquine inhibits the NF-κB and IKK signaling pathways, suppresses NF-κB-Luc luciferase activity, blocks the activation of p65 and IκBα, and reduces the expression of downstream target genes of NF-κB. (Rac)-Mefloquine activates apoptosis-related factors and induces apoptosis in tumor cells. (Rac)-Mefloquine functions as a tumor cell inhibitor. (Rac)-Mefloquine can be used for the research of colorectal cancer .
    (Rac)-Mefloquine
  • HY-182026
    FXR agonist 17

    		FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Reactive Oxygen Species (ROS) Inflammation/Immunology
    FXR agonist 17 is an orally active, steroidal FXR agonist with EC50 values of 42.2 nM (TR-FRET) and 176.4 nM (luciferase reporter assay), respectively. FXR agonist 17 activates TGR5 (EC50 = 2.6 μM) but does not activate hMRGPRX4. FXR agonist 17 exerts anti-inflammatory, hepatoprotective and antifibrotic effects, improves the non-alcoholic steatohepatitis (NAFLD) activity score and reduces the severity of liver fibrosis. FXR agonist 17 can be used for the research of NAFLD, cholestatic liver disease and liver fibrosis .
    FXR agonist 17
  • HY-W585917
    Bisphenol F bis(2-chloro-1-propanol) ether

    BFDGE·2HCl

    		 Androgen Receptor Metabolic Disease
    Bisphenol F bis(2-chloro-1-propanol) ether (BFDGE·2HCl) is an androgen receptor antagonist with a human IC50 of 18 μM. Bisphenol F bis(2-chloro-1-propanol) ether binds to the androgen receptor. Bisphenol F bis(2-chloro-1-propanol) ether (BFDGE·2HCl) can be used for research on hormonal activity .
    Bisphenol F bis(2-chloro-1-propanol) ether

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: